Table 3.
Antimicrobial susceptibility of Carbapenem-resistant Enterobacterales (CRE) isolates at local clinical laboratories, by epidemiological classification, 2012-2015, n = 1499
| Antimicrobial agent | Number susceptible/ Total number tested (%) |
P-value | ||
|---|---|---|---|---|
| All, n = 1499 | CA, n = 149 | HCA, n = 1350 | ||
| Aminoglycosides | ||||
| Any tested | 1253/1473 (85.1) | 141/146 (96.6) | 1112/1327 (83.8) | <.0001 |
| Amikacin | 875/1286 (68.0) | 112/118 (94.9) | 763/1168 (65.3) | <.0001 |
| Gentamicin | 973/1462 (66.6) | 129/145 (89.0) | 844/1317 (64.1) | <.0001 |
| Tobramycin | 534/1325 (39.9) | 88/113 (77.9) | 436/1212 (36.0) | <.0001 |
| Fluoroquinolones | ||||
| Any tested | 454/1465 (31.0) | 102/145 (70.3) | 352/1320 (26.7) | <.0001 |
| Ciprofloxacin | 391/1314 (29.8) | 98/142 (69.0) | 293/1172 (25.0) | <.0001 |
| Levofloxacin | 328/1133 (29.0) | 63/98 (64.3) | 265/1035 (25.4) | <.0001 |
| Other antimicrobials | ||||
| Ampicillin | 34/1295 (2.6) | 22/121 (18.2) | 12/1174 (1.0) | <.0001 |
| Aztreonam | 87/1161 (7.5) | 35/105 (33.3) | 52/1056 (4.9) | <.0001 |
| Colistin* | 194/222 (87.4) | 2/2 (100.0) | 192/220 (87.3) | .5894 |
| Piperacillin-tazobactam | 208/1397 (14.9) | 57/138 (41.3) | 151/1259 (12.0) | <.0001 |
| Nitrofurantoin | 90/377 (23.9) | 23/39 (59.0) | 67/338 (19.8) | <.0001 |
| Tigecycline* | 188/657 (28.6) | 11/28 (39.3) | 177/629 (28.1) | .2017 |
| Trimethoprim-sulfamethoxazole | 463/1456 (31.8) | 80/144 (55.6) | 383/1312 (29.2) | <.0001 |
CA, community-associated; HCA, health care-associated.
*
EUCAST Version 8.0 clinical breakpoints were applied for colistin and tigecycline (http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.0_Breakpoint_Tables.pdf).